Incomplete testosterone suppression with luteinizing hormone‐releasing hormone agonists: does it happen and does it matter?

促黄体激素 睾酮(贴片) 内分泌学 促性腺细胞 内科学 激素 医学
作者
Tom Pickles,Jeremy Hamm,William Morris,William E. Schreiber,Scott Tyldesley
出处
期刊:BJUI [Wiley]
卷期号:110 (11b) 被引量:54
标识
DOI:10.1111/j.1464-410x.2012.11190.x
摘要

Study Type – Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Previous reports, with small numbers of patients, have described the problem of incomplete testosterone suppression (>1.1 or 1.7 nmol/L) with LHRH agonists. Various predisposing factors have been suggested: different drug agents and patient factors such as age, pretreatment testosterone levels and weight. Such incomplete testosterone suppression has been shown in one small report to be associated with increased PSA failure rates and in another report in those with metastases, with worse survival. This study used testosterone assays that are more accurate at low levels than those used in most previous reports in a large dataset of 2196 men, and confirmed incomplete testosterone suppression (breakthrough) rates >1.7 nmol/L of 3.4% and >1.1 nmol/L of 6.6%. We showed that younger age was strongly associated with the risk of breakthrough, with a minor effect of increasing body mass index. Repeated breakthroughs were more common (16%) in those who had already had one breakthrough. Interim measures of cancer control (PSA kinetics during LHRH therapy) were inferior in those with a breakthrough, and those with breakthroughs between 1.1 and 1.7 nmol/L had worse long‐term biochemical control rates. OBJECTIVES To describe breakthrough rates above castrate levels of testosterone, in a population‐based series of men undergoing adjuvant luteinizing hormone‐releasing hormone (LHRH) agonist therapy with curative radiation therapy. To explore the predisposing factors for such breakthroughs and their impact on subsequent outcomes. PATIENTS AND METHODS All men treated for prostate cancer between 1998 and 2007 with curative radiation in the province of British Columbia, Canada were potentially eligible ( n = 11 752). Of these, 2196 fulfilled the eligibility criteria. Serial testosterone measurements were obtained during continuous LHRH therapy. Breakthrough rates >1.1 nmol/L and >1.7 nmol/L were calculated for each LHRH injection and for each patient course. Predisposing factors were identified, and early surrogates of oncological outcome (neoadjuvant nadir and post‐treatment nadir) were determined. RESULTS The risk of a breakthrough >1.1 nmol/L was 6.6%, and >1.7 nmol/L was 3.4% per patient course and 5.4% and 2.2% per LHRH injection (inclusive ranges). Repeated breakthroughs occurred in 16% of patients. Younger men were more liable to breakthroughs ( P < 0.001). Early PSA kinetic surrogates of cancer control were inferior in those with breakthroughs. Neither overall biochemical non‐evidence of disease (bNED) nor survival were compromised, although subgroup analysis showed inferior 5‐year bNED in those with breakthroughs of 1.1–1.7 nmol/L vs those without (58% vs 73%, respectively; P = 0.048). CONCLUSIONS Breakthroughs with LHRH agonists occur occasionally per injection, but occur commonly per patient course of treatment, and adversely affect early surrogate measures of outcome. The monitoring of testosterone levels during therapy is therefore advised.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CodeCraft应助廉凌波采纳,获得10
刚刚
2秒前
仁爱水之完成签到 ,获得积分10
2秒前
丫丫完成签到,获得积分10
4秒前
4秒前
4秒前
prime发布了新的文献求助10
5秒前
雨过天晴发布了新的文献求助10
6秒前
7秒前
7秒前
7秒前
天天快乐应助玛卡巴卡采纳,获得30
8秒前
xiaohu完成签到,获得积分10
8秒前
zm发布了新的文献求助10
10秒前
温暖的冰菱关注了科研通微信公众号
10秒前
程程发布了新的文献求助10
10秒前
乖猫要努力应助感动黄豆采纳,获得10
11秒前
潘善若发布了新的文献求助10
13秒前
anna发布了新的文献求助10
14秒前
15秒前
充电宝应助momo采纳,获得10
15秒前
勤奋梨愁完成签到,获得积分10
16秒前
summer完成签到,获得积分10
16秒前
17秒前
深情安青应助程程采纳,获得10
19秒前
张雯思发布了新的文献求助10
19秒前
格格完成签到 ,获得积分10
22秒前
22秒前
Hello应助下一秒采纳,获得10
25秒前
天天快乐应助科研通管家采纳,获得10
26秒前
赘婿应助科研通管家采纳,获得10
26秒前
搜集达人应助科研通管家采纳,获得10
26秒前
桐桐应助科研通管家采纳,获得10
26秒前
科研通AI5应助科研通管家采纳,获得10
26秒前
28秒前
28秒前
刘娅铷完成签到,获得积分10
28秒前
29秒前
英俊的铭应助全若之采纳,获得10
30秒前
可爱的函函应助绛川采纳,获得10
31秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989263
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253814
捐赠科研通 3270066
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136